New drugs for schizophrenia: An update for family physicians

American Family Physician

Volumn 56, Issue 4, 1997, Pages 1149-1156

  Amadio, Patricia B ^a   Cross, L Brian ^b   Amadio Jr , Peter ^c  

^a MAYO CLINIC   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMITRIPTYLINE PLUS PERPHENAZINE; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; CHARCOAL; CHLORPROMAZINE; CHLORPROTHIXENE; CHOLINERGIC RECEPTOR; CLOZAPINE; DIBENZOXAZEPINE DERIVATIVE; DROPERIDOL; ERYTHROMYCIN; FENTANYL; FLUPHENAZINE; HALOPERIDOL; LITHIUM; LOXAPINE; LOXAPINE SUCCINATE; MESORIDAZINE; MESORIDAZINE BESYLATE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PROCHLORPERAZINE; PROCHLORPERAZINE MALEATE; PROMAZINE; PROZINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; TRIFLUPROMAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTICHOLINERGIC EFFECT; ARTICLE; EXTRAPYRAMIDAL SYMPTOM; GENERAL PRACTITIONER; HUMAN; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; SCHIZOPHRENIA; SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; EXTRAPYRAMIDAL TRACTS; HUMANS; SCHIZOPHRENIA;

EID: 0030845798     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders-DSM-IV. 4th ed. Washington, D.C.: American Psychiatric Association, 1994.
2. Williams R, Dickson RA. Economics of schizophrenia. Can J Psychiatry 1995;40(7 Suppl 2):S60-7.
3. Lieberman JA. Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 1993;54(Suppl):13-7.
4. Owens DG. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 1994;55(Suppl):29-35.
5. Huttunen M. The evolution of the serotonin-dopamine antagonist concept. J Clin Psychopharmacology 1995;15(Suppl 1):4S-10S.
6. Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 1994;55 Suppl:5-12.
7. Wiesel FA, Nordstrom AL, Farde L, Eriksson B. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology (Berl) 1994;114:31-8.
8. Breier A. Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res 1995;14:187-202.
9. Gratz SS, Levinson DF, Simpson GM. Neuroleptic malignant syndrome. In: Kane JM, Lieberman JA, eds. Adverse effects of psychotropic drugs. New York: Guilford Press, 1992:266-84.
10. Mills KC. Serotonin syndrome. Am Fam Physician 1995;52:1475-82.
11. Martin TG. Serotonin syndrome. Ann Emerg Med 1996;28:520-6.
12. Cohen LJ. Risperidone. Pharmacotherapy 1994;14:253-65.
13. McEvoy JP. Efficacy of risperidone on positive features of schizophrenia. J Clin Psychiatry 1994;55 Suppl:18-21.
14. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40 (Published erratum appears in J Clin Psychopharmacol 1993;13:149).
15. Janicak PG, Sadek HS. Risperidone: A new, novel (and better?) antipsychotic. Psychiatric Annals 1996;26:78-87.
16. Webster P, Wijeratne C. Risperidone-induced neuroleptic malignant syndrome [Letter]. Lancet 1994;344(8931):1228-9.
17. Mahmood T, Clothier EB, Bridgman R. Risperidone-induced extrapyramidal reactions [Letter]. Lancet 1995;346(8984):1226.
18. McKeith IG, Ballard CG, Harrison RW. Neuroleptic sensitivity to risperidone in Lewy body dementia [Letter]. Lancet 1995;346:699.
19. Borison RL. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 1995;15(1 Suppl 1):24S-9S.